EXEL | Biotech Message Board Posts


Biotech   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  41877 of 42073  at  5/19/2022 12:40:36 PM  by

Boonedog


EXEL

For long-term investors (>2 years), today's 15% drop on reports that a patent judge might rule (as largely expected) in favor of MSN polymorph of cabozantinib while protecting the other, broader EXEL patent(s) could be good opportunity. $2B in cash and no debt on $6B market cap with $1B+ product revenues, several catalysts over the next 18 months, and a next gen Cabo in the pipeline...https://seekingalpha.com/news/3841029-exelixis-drops-quickly-on-day-four-of-cabometyx-patent-trial


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 5  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...